Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 50Years
MALE
NCT06270316

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

Led by UniQure Biopharma B.V. · Updated on 2025-10-23

12

Participants Needed

8

Research Sites

360 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The main goals of this clinical study are to characterize safety and PK/PD of AMT-191 i.e. if drug doses used in the study are safe and tolerable and to understand how it acts in the body of people with Fabry disease.

CONDITIONS

Official Title

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

Who Can Participate

Age: 18Years - 50Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male aged 18 to 50 years
  • Confirmed diagnosis of classic Fabry disease defined by either absent or minimal alpha-galactosidase A enzyme activity or a genetic variant associated with classic Fabry disease and low enzyme activity
  • Estimated glomerular filtration rate (eGFR) of 40 mL/min/1.73 m2 or higher
  • Suboptimal response after at least 12 months of enzyme replacement therapy, including plasma lyso-Gb3 level of 2.3 ng/mL or higher and either persistent moderate or severe neuropathic pain for at least 3 months or moderate to severe gastrointestinal symptoms occurring two or more times in the prior 12 weeks
  • Weight of 120 kilograms or less
Not Eligible

You will not qualify if you...

  • Allergic reaction to enzyme replacement therapy or infusion reaction within 12 months prior to consent that was severe and required emergency treatment
  • Proteinuria with urine protein/creatinine ratio of 1 mg/mg or higher at screening
  • Current use of chaperone therapy such as migalastat
  • History of cancer within 5 years except basal or squamous cell skin cancer
  • Active or latent hepatitis B or C, HIV, or tuberculosis infection
  • Significant uncontrolled medical conditions including renal, liver, heart, blood, gastrointestinal, endocrine, lung, neurological, psychiatric diseases, alcoholism, drug dependency, or psychological disorders impacting safety or study adherence
  • Liver disease such as hepatitis, fibrosis, cirrhosis, or tumor
  • History of kidney transplant or current dialysis treatment
  • Uncontrolled hypertension confirmed by repeated measurements
  • Glycated hemoglobin (HbA1c) of 7% or higher at screening
  • Contraindications to systemic corticosteroid or immunosuppressive therapy
  • Chronic steroid use of 3 months or more within 12 months prior to screening
  • Abnormal liver or kidney function laboratory values exceeding twice the upper limit of normal
  • Low hemoglobin, low platelet count, elevated INR, or elevated soluble terminal complement complex
  • Significant kidney abnormalities on ultrasound such as single kidney, large size difference, or cysts

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 8 locations

1

The Kirklin Clinic Of university of Alabama Birmingham Hospital

Birmingham, Alabama, United States, 35233

Actively Recruiting

2

Emory University School of Medicine

Atlanta, Georgia, United States, 30322

Actively Recruiting

3

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States, 60611

Actively Recruiting

4

MHealth Fairview University of Minnesota Medical Center East Bank

Minneapolis, Minnesota, United States, 55455

Actively Recruiting

5

NYC Health + Hospitals/Metropolitan

New York, New York, United States, 10029

Actively Recruiting

6

UPMC Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15224

Actively Recruiting

7

University of Utah, Clinical and Translational Sciences Institute

Salt Lake City, Utah, United States, 84108

Actively Recruiting

8

Lysosomal & Rare Disorders Research and Treatment Center, Inc

Fairfax, Virginia, United States, 22030

Actively Recruiting

Loading map...

Research Team

U

uniQure

CONTACT

C

Christy Quintana

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease | DecenTrialz